For the first time, a drug has meaningfully improved on that standard.
For generations, a diagnosis of chronic hepatitis B has meant a lifelong negotiation with medication—the virus held in check but never truly defeated, the threat of cirrhosis and cancer always present. GlaxoSmithKline has now presented evidence from trials spanning 29 countries that their experimental drug bepirovirsen may rewrite that sentence: in roughly one in five patients, the immune system learns to control the infection on its own, rendering the virus undetectable long after treatment ends. It is the first time a drug with a genuinely different mechanism has achieved what medicine calls a functional cure in this disease, and for 240 million people living under its shadow, the implications are historic.
- Chronic hepatitis B has long been a life sentence of daily medication, with fewer than one in a hundred patients ever escaping the virus's grip—a ceiling that bepirovirsen has now shattered by achieving functional cure in 19% of trial participants.
- The drug's novelty lies not in suppression but in education: it appears to retrain the immune system to recognize and control the infection independently, opening the door to treatment that ends rather than merely continues.
- Data from over 1,800 patients across 29 countries, published in The New England Journal of Medicine and presented in Barcelona, give the findings unusual weight—this is not a preliminary signal but a large, multinational confirmation.
- Beyond those fully cured, many more patients showed dramatic reductions in viral activity, translating to measurably lower risks of liver failure, cirrhosis, and hepatocellular carcinoma—diseases that currently kill hundreds of thousands each year.
- The path forward now runs through regulatory agencies and health systems: the science has moved, but the distance between a trial result and a pill in the hands of a patient in a low-income country remains vast and uncertain.
Somewhere in the world right now, a person is taking a pill for hepatitis B—and expects to take it for the rest of their life. That has been the unbroken reality for the 240 million people living with chronic infection: the virus settles into the liver, the immune system cannot clear it alone, and so the medication continues, year after year, holding the disease at bay but never ending it. Cirrhosis, liver failure, and cancer wait at the far end of that road. Until now, there has been no real exit.
GlaxoSmithKline has presented results that could change this entirely. Their experimental drug, bepirovirsen, does not simply suppress the virus the way existing antivirals do. It appears to teach the immune system to control the infection on its own—so that patients might eventually stop treatment and remain virus-free. Researchers call this a functional cure: the virus becomes undetectable in the blood for at least six months after treatment ends, held in check by the body's own defenses.
The evidence comes from two large phase III trials, B-Well 1 and B-Well 2, enrolling more than 1,800 patients across 29 countries. Published in The New England Journal of Medicine and presented at the European Congress of Hepatology in Barcelona, the results showed approximately 19% of bepirovirsen patients achieving functional cure—rising to 26% among those who began the trial with lower baseline viral markers. Against a backdrop where current treatments cure fewer than one in a hundred patients, these figures represent a genuine threshold crossed.
Many more patients who did not reach full cure still showed substantial reductions in viral activity, with meaningful consequences: less ongoing liver damage, lower risk of serious complications, and a significant decrease in the likelihood of developing liver cancer. The safety profile proved manageable, with injection-site reactions and temporary enzyme elevations as the principal side effects.
Dr. María Buti of Vall d'Hebron, who participated in the trials, described the moment as historically significant—the first time a drug with a fundamentally different mechanism has successfully cured a group of chronic hepatitis B patients. The question medicine is now asking is not whether bepirovirsen works, but how swiftly it can move through regulatory approval and reach the global population that has been waiting, pill by pill, for precisely this possibility.
Somewhere in the world right now, a person is taking a pill for hepatitis B—and will keep taking it for the rest of their life. That has been the reality for the 240 million people living with chronic hepatitis B infection. The virus settles into the liver, the immune system cannot clear it alone, and so the medication continues: year after year, decade after decade, holding the infection at bay but never truly ending it. The disease can progress to cirrhosis, liver failure, or cancer. Until now, there has been no real exit.
GlaxoSmithKline has just presented results that could change this calculus. Their experimental drug, bepirovirsen, works differently from the antivirals currently in use. Rather than simply suppressing the virus, it appears to train the immune system to control the infection on its own—meaning patients might eventually stop taking medication altogether and remain virus-free. This is what researchers call a functional cure: the virus becomes undetectable in the blood for at least six months after treatment ends, and stays that way because the body's defenses have learned to keep it in check.
The evidence comes from two large phase III trials, called B-Well 1 and B-Well 2, which enrolled more than 1,800 patients across 29 countries. The results were published in The New England Journal of Medicine and presented at the European Congress of Hepatology in Barcelona. Among patients treated with bepirovirsen, approximately 19 percent achieved functional cure. In certain subgroups—those who started the trial with lower levels of hepatitis B surface antigen—the rate climbed to 26 percent. These numbers may sound modest until you consider the baseline: with current treatments, fewer than one in a hundred patients ever reaches functional cure. For the first time, a drug has meaningfully improved on that standard.
Beyond those who achieved complete cure, many more patients showed substantial reduction in viral activity. This matters because it translates to less ongoing liver damage, lower risk of developing serious complications, and—critically—a significant decrease in the likelihood of developing hepatocellular carcinoma and dying from the disease. The loss of hepatitis B surface antigen from the blood is itself a major protective event, associated with dramatically reduced cancer and mortality risk.
The safety profile appears manageable. The most common side effects were redness and pain at the injection site, along with temporary elevations in liver enzymes—findings consistent with earlier-stage studies. Nothing emerged to suggest the drug is unsafe for the patient populations studied.
Dr. María Buti, a researcher at Vall d'Hebron who participated in the trials, emphasized the historical significance: this is the first time a drug with a fundamentally different mechanism of action has successfully cured a group of chronic hepatitis B patients. International specialists are already discussing how treatment approaches might shift in the coming years. The question now is not whether bepirovirsen works, but how quickly it can move through regulatory approval and into clinical practice, and how it will be deployed across the global population that desperately needs it.
Citações Notáveis
This is the first time a drug with a fundamentally different mechanism of action has successfully cured a group of chronic hepatitis B patients.— Dr. María Buti, Vall d'Hebron researcher and trial participant
A Conversa do Hearth Outra perspectiva sobre a história
Why does functional cure matter so much more than just controlling the virus?
Because control is exhausting. You take a pill every day for decades. Miss a dose, and the virus can rebound. But if your immune system learns to do the job itself, you're actually free—no pills, no monitoring, no fear of what happens if you stop.
And 19 percent is really a breakthrough?
It is when you're starting from less than one percent. We're not talking about a marginal improvement. We're talking about a tenfold jump. For a disease that affects a quarter-billion people, that's millions of lives that could change.
What about the people who don't achieve cure? Are they worse off?
No. Even those who don't reach full cure often see their viral load drop significantly. That means less scarring of the liver, lower cancer risk. They may still need medication, but they're in a better position than they would have been.
How does this drug actually work differently?
Current antivirals are like a cage around the virus—they keep it trapped. Bepirovirsen is more like a training program for the immune system. It teaches your body's defenses to recognize and control the infection themselves.
When will patients actually be able to get this?
That's the next hurdle. Regulatory approval takes time. But the trials are done, the data is solid, and specialists are already thinking about how to implement it. Within a few years, probably.